May accelerate response in major depression and possibly offer a new option for treatment-resistant cases, but high cost and misuse potential limit its appeal.

Clomipramine is usually reserved for obsessive-compulsive disorder (OCD) when SSRIs are ineffective or poorly tolerated because of its higher side effect burden.

Desvenlafaxine, the active metabolite of venlafaxine, offers modest advantages—such as simpler dosing and fewer drug interactions.

Citalopram has a favorable profile—neither very sedating nor activating, with low drug–drug interaction risk.

First-line option for depression with fatigue or concentration deficits.

Zuranolone is a novel, fast-acting oral neurosteroid approved for severe postpartum depression (PPD). It offers rapid relief, good tolerability, and easier administration than its intravenous predecessor, brexanolone (now discontinued).

Adderall combines 75% dextroamphetamine and 25% levoamphetamine.

Viloxazine is a nonstimulant attention-deficit/hyperactivity disorder (ADHD) medication with no misuse potential and fewer side effects, like insomnia or tics, than stimulants.

Methylphenidate has a better side effect profile and somewhat lower abuse potential than amphetamines. However, patients often prefer the “kick” they get from Adderall.